The specific functions of plasminogen, stromal plasminogen activator, stromal plasminogen activator receptor, and stromal plasminogen activator inhibitor in the progression of the murine soft tissue sarcoma, T241 were investigated. Negation of plasminogen to the tumor blunted the orthotopic growth of the sarcoma in syngeneic mice. The reduced tumor growth was associated with a dramatic increase in tumor-infiltrating F4/80-positive macrophages and a diminution of vessel density, but not with obvious differences in fibrin and collagen deposition, or invasiveness of the tumor. Ablation of plasminogen activation by the tumor stroma only modestly impaired the prolonged growth of the sarcoma, suggesting that tumor cell-produced plasminogen activator is sufficient to mediate productive plasminogen activation. Plasminogen facilitated sarcoma progression, angiogenesis, and suppression of macrophage infiltration in the absence of either stromal urokinase plasminogen activator receptor or stromal plasminogen activator inhibitor. These data demonstrate that tumor cell-produced plasminogen activator and host plasminogen cooperate to facilitate soft tissue sarcoma growth and suppress the accumulation of tumor-infiltrating macrophages.
Introduction
The plasminogen activation (PA) system is an extracellular proteolytic system with pleiotropic functions in physiological and pathological tissue remodeling (Andreasen et al., 1997a (Andreasen et al., , 2000 Danø et al., 1999) . The PA system is a complex system of serine proteases, protease inhibitors, and protease receptors that governs the conversion of the protease zymogen, plasminogen (Plg), to the active serine protease, plasmin. Plg is predominantly produced by the liver and is present in a very high concentration in plasma and most extravascular fluids (Danø et al., 1985) . Plasmin is formed by the proteolytic cleavage of Plg by either of two Plg activators, the urokinase Plg activator (uPA) or the tissue Plg activator (tPA), of which uPA has attracted the most attention in the context of tumor progression. uPA is a 52 kDa serine protease that is secreted as a relatively inactive single chain zymogen (pro-uPA) that is efficiently converted to active two-chain uPA by plasmin, when bound to its cellular receptor, the uPAreceptor (uPAR) . Two-chain uPA, in turn, is a potent activator of Plg, leading to a powerful feedback loop and productive plasmin formation. Plasmin generated by the cell surface PA system is relatively protected from its primary physiological inhibitor a2-antiplasmin, leading to the notion that plasmin-mediated proteolysis is strictly associated with the cell surface Hall et al., 1991; . Both prouPA and Plg are catalytically virtually inactive proenzymes, and the mechanism of initiation of uPAmediated Plg activation is not fully understood. ProuPA may initially be activated by other proteases besides plasmin, or be capable of activating Plg via a very low intrinsic activity. The transmembrane serine protease matriptase/MT-SP1, true tissue kallikrein, hepatocyte growth factor activator, and cathepsin B are all candidate initiators of the tumor-associated prouPA cascade (Lee et al., 2000; List et al., 2000; Romisch et al., 1999; Takeuchi et al., 2000) . Cell surface Plg activation by uPA and tPA is regulated by either of two physiological inhibitors, Plg activator inhibitor-1 and -2 (PAI-1 and PAI-2), each forming a 1 : 1 complex with uPA (Baker et al., 1990; Cubellis et al., 1989; Ellis et al., 1990) .
The specific association of the PA system with malignant tumor progression is well documented (Andreasen et al., 1997a (Andreasen et al., , 2000 Danø et al., 1999) . Histological analysis of both human tumors and experimental mouse tumors have consistently demonstrated expression of the components of the PA system at sites of active invasion (Pyke et al., 1991a (Pyke et al., ,b, 1993 Skriver et al., 1984) . uPAR and uPA are overexpressed with remarkable consistency in malignant human tumors, including cancers of the head and neck (Schmidt et al., 2000) , colon (Pyke et al., 1991b) , breast (Dublin et al., 2000; Pyke et al., 1993) , bladder (Hudson and McReynolds, 1997) , liver (de Petro et al., 1998) , lung (Morita et al., 1998) , pancreas (Taniguchi et al., 1998) , and ovaries (Sier et al., 1998) , as well as in both monocytic and myelogenous leukemias (Lanza et al., 1998; Plesner et al., 1994) . Detailed in situ hybridization and immunohistochemical studies have revealed that cancer cells typically express uPAR, whereas uPA may be expressed either by cancer cells or by adjacent stromal cells, depending on tumor-type and origin Nielsen et al., 1996; Pyke et al., 1991a Pyke et al., , 1994 . Plg activators, uPAR, and PAI, are all excellent prognostic markers in human cancer, further implicating the PA system in tumor progression (Andreasen et al., 1997b (Andreasen et al., , 2000 . Thus, extensive epidemiological studies have revealed that high expression of Plg activator, uPAR, or PAI-1 in human breast (Duffy et al., 1990; Foekens et al., 1992; GrondahlHansen et al., 1993) , colorectal (Ganesh et al., 1994a,b) , lung (Oka et al., 1991; Pedersen et al., 1994) , prostate (Hienert et al., 1988) , and gastric cancer (Heiss et al., 1995; Nekarda et al., 1994) , is associated with a poor prognosis. The direct causal relationship between Plg activator expression and tumor progression was furthermore demonstrated in a number of studies using the chick chorio-allantoic membrane metastasis model, and the mouse spontaneous and experimental metastasis models. These studies have employed a variety of strategies to inhibit Plg activator function including antisense RNA techniques (Kook et al., 1994; Yu and Schultz, 1990) , anti-catalytic Plg activator antibodies (Hearing et al., 1988; Kobayashi et al., 1994b; Ossowski, 1988; Ossowski and Reich, 1983) , natural and synthetic Plg activator inhibitors or uPAR antagonists (Crowley et al., 1993; Kobayashi et al., 1994a; Min et al., 1996; Mueller et al., 1995; Rabbani et al., 1995) , and, lately, also genetically engineered mice with targeted deficiencies in components of the PA system (Bugge et al., 1997 (Bugge et al., , 1998 Sabapathy et al., 1997; Shapiro et al., 1996) . Collectively, these studies have firmly established the PA system as an important contributor to tumor progression.
Although the causal relation of expression of the PA system to malignant progression is now well documented, insights into the mechanistic details of how the PA system promotes the progression of tumors are still sparse. The direct molecular targets of plasmin in malignant progression and the biological pathways that are affected by tumor-associated Plg activation remain to be identified. Furthermore, the individual contributions of Plg, plasmin, stromal cell-produced Plg activator, tumor cell-produced Plg activator, stromal cell-produced PAI, tumor cell-produced PAI, stromal uPAR, and tumor cell uPAR to tumor progression are relatively undefined. Plasmin has a broad substrate specificity that is compatible with the degradation of several components of the basement membrane and the ECM during invasion, either directly, or indirectly through the activation of latent matrix metalloproteinases (Andreasen et al., 1997a (Andreasen et al., , 2000 Danø et al., 1985 Danø et al., , 1999 . However, the broad specificity of plasmin is also compatible with supporting tumor dissemination by the activation of growth promoting and angiogenic pathways, stimulation of cell migration, suppression of apoptosis, and the modulation of host tumor defense systems (Beck et al., 1999; Martin et al., 1999; Montgomery et al., 1994; Pilcher et al., 1997; Wahl and Kleinman, 1998; Whitelock et al., 1996) . Many components of the PA system appear to be able to promote tumor progression independently of plasmin formation, complicating the analysis of plasminmediated proteolysis in cancer. uPAR is a multifunctional protein that is a key regulator of cell adhesion, cell migration, chemotaxis, and tumor cell proliferation, besides promoting cell surface plasmin formation (Blasi, 1999; Chapman and Wei, 2001; Ossowski and Aguirre-Ghiso, 2000) . Likewise, both non-proteolytic, cytokine-like functions and proteolytic, non-Plg related functions of tPA were recently demonstrated in pathologic tissue remodeling (Nicole et al., 2001; Rogove et al., 1999) . Furthermore, PAI-1 regulates cell adhesion and migration through a direct interaction with vitronectin and integrins, in addition to inhibiting Plg activators (Loskutoff et al., 1999; McMahon et al., 2001; Stefansson and Lawrence, 1996; Stefansson et al., 2001) . Taken together, the pleiotropic functions of the PA system make the identification of its critical downstream molecular targets during tumor progression a challenging undertaking.
In this study, we performed a comprehensive genetic and histological analysis of the contribution of components of the PA system to tumor progression. We chose as a simple model system a soft tissue sarcoma transplanted to the orthotopic connective tissue of syngeneic mice. This tumor expresses uPA, tPA, and PAI-1, but not Plg (see below). We report that host Plg and tumor cell-produced Plg activator cooperate to suppress the accumulation of tumorinfiltrating macrophages, and promote tumor growth and angiogenesis independently of host Plg activator, PAI-1, and uPAR.
Results
Orthotopically growing T241 fibrosarcoma express plasminogen activators and inhibitor, but not Plg
We initially investigated the expression of components of the Plg activation system by T241 fibrosarcoma after transplantation to orthotopic intradermal connective tissue. Pure samples of tumor tissue were procured by laser capture microdissection to avoid the potentially confounding contamination of the tumor samples by the surrounding epidermis and dermal non-tumor tissue and by fibrin-rich necrotic tumor and stromal tissue. uPA, tPA, and PAI-1 were all abundantly expressed in the tumor as visualized by casein-Plg zymography and Western blot analysis, respectively (Figure 1a,b) . Interestingly, tumor tissue dissected from mice with a combined deficiency in uPA and tPA (uPA7/7/tPA7/7) or from PAI-1-deficient mice (PAI-17/7) did not present a marked reduction in total uPA and tPA activity or PAI-1 antigen, suggesting that the two Plg activators as well as PAI-1 are predominantly produced by the tumor cells. In contrast, the T241 tumor did not produce detectable amounts of Plg as determined by Northern blot analysis (Figure 1c ).
Plg promotes tumor growth and vascularization and suppresses the accumulation of tumor-infiltrating macrophages
Tumor cells were transplanted to the intradermal space of syngeneic mice with single and combined deficiencies in the PA system. The macroscopic expansion of the tumor mass was followed until tumor morbidity necessitated the termination of the experiment. First, tumor cells were injected into Plg-deficient (Plg7/7) mice and matched control mice to determine the overall effect of wholesale loss of Plg on orthotopic growth of T-241 fibrosarcoma (Figure 2 ). The complete ablation of Plg did not prevent sarcoma growth but was associated with a significant reduction in tumor burden, as observed previously for carcinoma growth in Plg7/7 mice (Bugge et al., 1997) . This reduction was apparent at the earliest time point where tumor volumes could be determined and persisted throughout the observation period (Figure 2 ). The marked effect of Plg deficiency on primary tumor growth precluded a meaningful analysis of the function of Plg in distant We next carried out a detailed histological and immunohistochemical analyses of tumors growing in the presence and absence of Plg to gain insight into the mechanism by which Plg promotes sarcoma progression. Plg7/7 mice and Plg+/+ mice were inoculated with tumor cells, and the ensuing tumor nodules were excised and analysed 1 and 2 weeks after inoculation (Figures 3 and 4) . The microscopic appearance of Plg-containing and Plg-deprived tumors appeared superficially similar in the two groups when analysed by hematoxylin/eosin or Masson's trichrome staining ( Figure 3 and data not shown). Plg-deprived tumors clearly retained the capacity to invade the surrounding tissue, as evidenced by the invasion, separation, and destruction of bundles of muscle fibers in the panniculus (Figure 3a ,b) and the invasion and destruction of the upper layers of the epidermis (data not shown). Fibrin(ogen) immunostaining revealed a diffuse deposition of fibrin(ogen) around healthy tumor cells, and more prominent fibrin(ogen) deposition at the invasive front of the tumors, in areas of frank necrosis, and lining the tumor vasculature (Figure 3c ,d). As described previously for both mammary adenocarcinoma and lung carcinoma (Bugge et al., 1997 (Bugge et al., , 1998 , loss of Plg did not lead to an obvious increase in tumor-associated fibrin(ogen) deposition, suggesting that proteases different from Plg can serve as fibrinolysins in the context of tumor progression (Hiraoka et al., 1998; Hotary et al., 2002) . Plg-sufficient and Plg-deprived tumors did also not demonstrate an obvious difference in the deposition of collagen, as visualized by Masson's Trichrome staining (data not shown). We next assessed the role of Plg in the recruitment of cellular components to the tumor stroma, which consists predominantly of macrophages, endothelial cells, and fibroblast-like cells. Macrophages were highly abundant in the tumor stroma of Plg-sufficient tumors, constituting on average 17% of all cells in the tumor as assessed by F4/80 immunostaining ( Figures  3f and 4a) . Interestingly, the density of tumorinfiltrating macrophages was about twice as high in the stroma of Plg-deprived tumors when analysed both 1 and 2 weeks after tumor cell inoculation (Day 7: 54+3 versus 30+3 F4/80-positive cells per highpowered field (HPF) in Plg-deprived and Plg-sufficient tumors, respectively; P=0.00004. Day 15: 102+12 versus 50+4 F4/80-positive cells per HPF in Plgdeprived and Plg-sufficient tumors, respectively; P=0.0003) (Figures 3e and 4a ). This increase did not appear to be related to a generalized increase in tissue macrophages in the Plg7/7 mice, as tumor bearing Plg7/7 and Plg+/+ mice displayed a similar number of alveolar macrophages (10.8+1.3 versus 11.0+1.0 F4/80-positive cells per HPF in Plg7/7 and Plg+/+ mice, respectively). No significant difference was observed in the vessel density of Plg-sufficient and Plg-deprived tumors after 1 week of intradermal growth, demonstrating that Plg is dispensable for the formation of an initial tumor vasculature (4.17+0.29 versus 3.54+0.56 vessels per HPF in Plgdeprived and Plg-sufficient tumors, respectively) (Figures 3g,h and 4b). However, Plg deprivation was associated with an approximately 40% reduction in vessel density after 2 weeks, when the tumor mass was undergoing dramatic expansion (1.83+0.32 versus 2.94+0.24 vessels per HPF in Plg-deprived and Plgsufficient tumors, respectively; P=0.01). Stromal fibroblasts could not be distinguished unambiguously from fibrosarcoma cells and therefore no attempt was made to quantitate the density of stromal fibroblasts. Cell proliferation was vigorous in both Plg-sufficient and Plg-deprived tumors (Figures 3i, j and 4c) . Approximately 17% of the cells in the tumors were in the S phase of the cell cycle, as evidenced by the incorporation of BrdU, with no apparent difference between Plg-sufficient and Plg-deprived tumors (51+3 versus 50+2 BrdU-positive cells per HPF in Plgdeprived and Plg-sufficient tumors, respectively). In contrast, the rate of apoptosis was very low in both Plg-deprived and Plg-sufficient tumors with, on average, less than 1% of the cells presenting as apoptotic bodies, as visualized by TUNEL staining (Figures 3k,l and 4d ). The identity of the apoptotic bodies (tumor cells or stromal cells) could not be readily determined. Plg-deprived tumors displayed a small, but not significant, increase in apoptotic bodies (2.93+0.58 versus 2.14+0.46 apoptotic nuclei per HPF in Plg-deprived and Plg-sufficient tumors, respectively; P=0.29).
Figure 2 Plg deficiency attenuates orthotopic fibrosarcoma growth. Plg7/7 mice (diamonds) (n=10) and control mice (squares) (n=11) were inoculated intradermally with T241 fibrosarcoma and the weight of the ensuing intradermal tumor nodules was determined as described in Materials and methods. The data are expressed as the mean tumor weight+the standard error of the mean. *P50.02 and **P50.003, Wilcoxon rank-sum test, two-tailed Tumor produced Plg activator and Plg cooperate to suppress macrophage accumulation and promote angiogenesis independent of stromal uPAR Macrophages express Plg activator and uPAR and are dependent on uPAR for productive cell surface plasmin generation (Bugge et al., 1995b) . uPA7/7/tPA7/7 mice have no macrophage-associated plasmin formation. However, tumor cells transplanted to these mice retain the potential for tumor cell surface-generation of plasmin. We therefore used the uPA7/7/tPA7/7 mice as a tool to determine if the alleviation of suppression of tumor-infiltrating macrophages in Plg- Histological analysis of tumor development in Plg7/7 mice. Plg7/7 (black bars) and control (white bars) mice were inoculated intradermally with fibrosarcoma cells. The ensuing intradermal tumors were excised on both day 7 and 15 and analysed for tumor-infiltrating macrophages by F4/80 immunostaining (a), vessel density by PECAM-1 immunostaining (b), cell proliferation by BrdU incorporation (c), and apoptosis by TUNEL staining (d). Nine tumors from Plg7/7 mice were analysed on day 7 and 15. Seven control tumors were analysed on day 7 and 11 on day 15. *P=0.01, **P=0.0003, ***P=0.00004, Student's t-test, two-tailed. Data are expressed as mean+standard error of the mean
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A Curino et al deprived tumors was related to the loss of macrophagegenerated plasmin, or rather was a direct consequence of the abrogation of tumor cell-generated plasmin. uPA7/7/tPA7/7 mice and control mice were inoculated with tumor cells, and the density of macrophages in the ensuing tumors was determined (Figure 5a ). Complete loss of macrophage-generated plasmin was only associated with a very modest, though significant, increase in the accumulation of tumor-infiltrating F4/80-positive cells from approximately 15 -19% of the cells in the tumor (56+1 versus 43+1 F4/80 positive cells per HPF in uPA7/7/ tPA7/7 and control mice, respectively; P=0.0002).
The absence of a pronounced effect of loss of Plg activator function by macrophages (and other stromal cells) suggests that the suppression of the accumulation of tumor-infiltrating macrophages by plasmin is predominantly associated with the expression of Plg activator by the tumor cells. We next quantitated the density of vessels in tumors growing in uPA7/7/ tPA7/7 and control mice by PECAM-1 staining, to directly assess the effect of the loss of stromal Plg activator function on tumor vascularization ( Figure  5b ). No difference in vessel density was present in the tumors of the two groups of mice, indicating that tumor cell-produced Plg activator is responsible for Plg-dependent stimulation of tumor angiogenesis (2.70+0.10 versus 2.73+0.23 vessels per HPF in tumors of uPA7/7/tPA7/7 and control mice, respectively). uPA-dependent cell-surface Plg activation is mediated by uPAR . uPAR can be expressed by tumor cells, fibroblast-like cells, sprouting tumor endothelial cells, and tumor-infiltrating macrophages depending on the tumor type Solberg et al., 2001) . uPA secreted by the tumor cells could therefore activate Plg on the surface of tumor cells, stromal cells, or both, to suppress the accumulation of tumor-infiltrating macrophages and promote angiogenesis. uPAR-deficient (uPAR7/7) mice do not express uPAR on stromal cells, but retain the capacity for uPAR-dependent activation of Plg on the surface of the transplanted tumor cells. The density of macrophages and vessels in tumors developing in uPAR7/7 mice and control mice was quantitated to directly determine the role of stromal uPAR expression on the suppression of the accumulation of tumorinfiltrating macrophages and angiogenesis ( Figure  5c,d) . No differences were observed in either the density of tumor-infiltrating macrophages (60+3 versus 58+4 F4/80 positive cells per HPF in tumors of uPAR7/7 and control mice, respectively), or vessel density (2.80+0.25 versus 2.50+0.39 vessels per HPF in tumors of uPAR7/7 and control mice, respectively). Taken together, these results strongly suggest that activation of Plg on the tumor cell surface by tumor cell-produced Plg activator suppresses the accumulation of tumor-infiltrating macrophages and promotes angiogenesis.
Effect of the loss of stromal uPA, tPA, uPAR, and PAI-1 on fibrosarcoma growth
We next addressed the overall importance of stromal cell-produced Plg activator, uPAR and PAI-1 on the growth of T241 fibrosarcoma by measuring the intradermal tumor growth rate in uPA7/7/tPA7/ 7, uPA7/7, tPA7/7, uPAR7/7, and PAI7/7 mice (Figures 6 and 7) . The combined loss of stromal uPA and tPA did not have a major effect on fibrosarcoma growth. However, a slight growth delay was occasionally noted after prolonged growth of the tumor in uPA7/7/tPA7/7 and uPA7/7 mice, but not in tPA7/7 mice (Figure 6a and data not shown). This growth disparity relative to control mice became apparent after about two weeks of intradermal growth, eventually leading to a 40 -60% reduction in tumor size as compared to control mice (Figure 6a and data not shown). In contrast, no impairment of intradermal fibrosarcoma growth was observed in uPAR7/7 Figure 5 Effect of loss of stromal Plg activator and uPAR on the accumulation of tumor-infiltrating macrophages and angiogenesis. Macrophage density (a) and vessel density (b) was determined at day 13 in tumors from uPA7/7/tPA7/7 (black bars) mice (n=5) and control (white bars) mice (n=5). *P=0.0002, Student's t-test, two-tailed. (c) Macrophage density and (d) vessel density were determined at day 16 in tumors from uPAR7/7 (black bars) mice (n=5) and control (white bars) mice (n=5). All data are expressed as mean+standard error of the mean mice, indicating that tumor-produced uPA promotes fibrosarcoma growth independently of stromal uPAR expression (Figure 6b ).
Stromal PAI-1 has a pivotal function in the vascularization and growth of many tumors (Bajou et al., 1998; McMahon et al., 2001) . We therefore measured the growth rate of fibrosarcoma transplanted to PAI-17/7 and control mice, to determine the role of stromal PAI-1 expression for orthotopic fibrosarcoma growth and vascularization (Figure 7) . Interestingly, no difference in the rate of tumor expansion was observed in the two groups of mice, demonstrating that stromal PAI-1 is dispensable for the overall growth of this type of tumor (Figure 7a) . Loss of stromal PAI expression also did not adversely affect the density of vessels in the tumors as assessed by PECAM-1 staining, suggesting that tumor cellproduced PAI-1 in this tumor model is sufficient to orchestrate the assembly of a functional tumor vasculature (2.27+0.27 versus 2.69+0.26 vessels per HPF in tumors of PAI7/7 and control mice, respectively) ( Figure 7b ).
Discussion
A substantial body of literature associates the PA system with the progression of malignant tumors. Expression, epidemiological, cell culture, overexpression, inhibitor, and genetic studies have all converged to link Plg activator, uPAR, and PAI-1 to tumor growth, invasion, angiogenesis, intravasation, extravasation, metastasis, morbidity, and mortality. Despite the unequivocal causal relation between expression of the PA system by tumors and the acceleration of tumor progression, knowledge of the critical downstream targets of the PA system in this important pathological process is still quite limited. Several factors complicate the identification of the molecular targets of the PA system in cancer. One complicating factor is the broad substrate specificity of plasmin, which is endowed with the capacity to directly degrade multiple substrates as well as activating other proteolytic cascades (see Introduction). This property of plasmin makes essentially all extracellular proteins potential targets for the PA system in cancer. Second, the PA system may exert its tumor-promoting function by acting on a diverse array of pathological processes such as inhibition of cell differentiation, stimulation of growth promoting pathways, inhibition of growth inhibitory pathways, suppression of apoptosis, stimulation of angiogenesis, dissociation of cell -cell and cellmatrix adhesions, promotion of cell migration, chemotaxis, and suppression of tumor immune surveillance. Third, uPA, tPA, uPAR, and PAI-1 all have individual functions that are unrelated to the activation of Plg. Figure 6 Effect of loss of stromal Plg activator and uPAR on fibrosarcoma growth. (a) uPA7/7/tPA7/7 (diamonds) mice (n=10) and control (squares) mice (n=10) and, (b) uPAR7/7 (diamonds) mice (n=10) and control (squares) mice (n=10) were inoculated intradermally with T241 fibrosarcoma and the weight of the ensuing intradermal tumor nodules was determined by calipation. *P50.03, Wilcoxon rank-sum test. Data are expressed as mean+standard error of the mean Figure 7 Effect of loss of stromal PAI-1 on fibrosarcoma growth and angiogenesis. PAI-17/7 (diamonds) (n=15) and control (squares) mice (n=15) were inoculated intradermally with T241 fibrosarcoma and the weight of the ensuing intradermal tumor nodules was determined by calipation. (b) Vessel density was determined at day 18 in tumors from PAI7/7 mice (black bars) (n=10) and control mice (white bars) (n=9). The data are expressed as mean+standard error of the mean Fourth, the specific contribution of the PA system to malignant progression may vary from tumor type to tumor type and for each stage of tumor progression. Fifth, some activities of the PA system may impede tumor progression and other activities promote progression. Therefore, the overall outcome of experimentally negating Plg, Plg activator, uPAR, or PAI-1 to tumors on measurable parameters such as growth, invasion, and angiogenesis, will represent the net sum of both the loss of tumor promoting and tumor inhibiting functions.
In this study we initiated an investigation aimed at obtaining a better understanding of the PA system in tumor progression. We chose, as a simple model system, to study the orthotopic growth of a fibrosarcoma in the intradermal space of syngeneic mice with single and combined genetic deficiencies in components of the PA system. Similar to other tumor models (Bugge et al., 1997; Sabapathy et al., 1997) , wholesale ablation of the PA cascade in this model system resulted in the impairment of the intradermal growth of the sarcoma, underscoring the importance of the PA system in tumor progression. The most conspicuous histological difference associated with Plg-deficiency resided in the density of tumor-infiltrating macrophages, which was approximately doubled in Plgdeprived tumors. A similar plasmin-mediated suppression of inflammatory cell recruitment has been observed in the context of bacterial infection (Goguen et al., 2000) . This increase appeared to be a direct consequence of the loss of plasmin-formation on the tumor cell surface, as the loss of either stromal cell produced Plg activator or stromal uPAR did not substantially affect the density of macrophages in the tumors. The T241 fibrosarcoma cells expressed high levels of both uPA and tPA in vivo as determined by laser capture microdissection. The contribution of each activator to Plg activation on the tumor cell surface could not be determined. However, intradermally growing T241 fibrosarcoma is exquisitely sensitive to treatment with a cell surface urokinase-activated anthrax toxin, suggesting that at least the uPAdependent Plg activation pathway is functional on the tumor cell surface (unpublished data). Further studies are needed to reveal the specific mechanism by which plasmin suppresses macrophage accumulation in tumors, but two likely possibilities include the proteolytic activation of growth factors and the proteolytic modification of the extracellular matrix (Rifkin et al., 1999; Werb, 1997) . Transforming growth factor-b1 is a powerful suppressor of inflammatory cell recruitment to tissues, and its proteolytic release from the latent transforming growth factor-b binding protein has been linked to plasmin (Kulkarni et al., 1993; Odekon et al., 1994; Sato et al., 1990; Shull et al., 1992) . Many cell types, including monocytes/macrophages, have specific receptors for fibrin and fibrin degradation products, and plasmin-generated fibrin degradation products have been reported to have immunosuppressive properties (Plow and Edgington, 1986; Simon et al., 1993) .
Macrophages are an abundant component of the stroma of both human tumors and experimental animal tumors. Multiple previous studies have been aimed at defining the functional properties of tumorinfiltrating macrophages and understanding their contribution to malignant progression (Elgert et al., 1998; Mantovani et al., 1992; Wahl and Kleinman, 1998) . It is tempting to speculate that the impaired growth of tumors in Plg-deficient mice in this study is directly associated with the increased density of macrophages. Indeed, tumor-infiltrating macrophages are directly toxic to tumor cells through their production of reactive oxygen intermediates, NO, H 2 O 2 , and tumor necrosis factor-a, and indirectly toxic through the production tumor immunity-stimulating interleukins (Alleva et al., 1994; Dinapoli et al., 1996; Elgert et al., 1998; Kono et al., 1996; Ohmori et al., 1995) . However, tumor-infiltrating macrophages are also endowed with potent tumor promoting properties. The release of platelet-derived growth factor, fibroblast growth factor, vascular endothelial growth factor, insulin-like growth factor, interleukin-1, transforming growth factor-a, and prostaglandins by tumor-infiltrating macrophages can stimulate tumor cell survival, proliferation, and angiogenesis (Leek et al., 1996 (Leek et al., , 2000 Sunderkotter et al., 1994) . Thus, the net effect of tumor-infiltrating macrophages on malignant dissemination appears to be dependent on tumor type, stage of tumor progression, and macrophage density.
The reduced rate of intradermal tumor expansion in Plg7/7 mice was not associated with an obvious blunting of invasive growth, as was also observed for tumors of epithelial origin (Bugge et al., 1997) . Invasive growth of tumor cells without accompanying ECM degradation is scarcely conceivable, suggesting that expression of other matrix degrading proteolytic systems beside the PA system are sufficient for invasive growth of this tumor. This finding, however, does not rule out the participation of the PA system in 'bulk proteolysis' of ECM during intradermal growth, but rather, shows that plasmin-mediated ECM degradation is not a rate-limiting step in the absence of other proteolytic deficiencies . Furthermore, the negation of Plg to tumors was also not associated with a reduction in the rate of cell proliferation as assessed by the enumeration of cells in the S phase of the cell cycle. This finding suggests that plasmin-mediated proteolysis as an isolated proteolytic entity is not critical for the activation or liberation of growth factors required for the proliferation of this type of tumor.
The formation and expansion of a functional vasculature is essential for tumor progression, and vessel density is a critical parameter in the rate of growth of transplanted and genetically induced tumors, including T241 fibrosarcoma. Vessel density correlates inversely with the rate of apoptosis, and anti-angiogenic agents can prevent malignant progression and even induce tumor dormancy (O'Reilly et al., 1994 (O'Reilly et al., , 1997 . Plg-deprived tumors displayed a moderate decrease in the density of vessels at late stages (average tumor weight, 0.45 g) of intradermal expansion but not at early stages (average tumor weight, 0.15 g). These data show that Plg is dispensable for the initiation of fibrosarcoma angiogenesis but contributes to the expansion of an established tumor vasculature, which may be a rate limiting step in the orthotopic progression of the tumor. However, we did not find a substantial increase in the rate of apoptosis in Plgdeprived tumors associated with this diminished vessel density, and the extent of necrotic cell death appeared to be reduced, rather than increased in Plg-deprived tumors (data not shown). It should be kept in mind that apoptotic bodies are cleared from tumors by macrophage-dependent phagocytosis (Platt et al., 1998) . It is likely that the density of tumor-infiltrating macrophages could critically influence the rate of clearance of apoptotic bodies, and, thus, the steadystate level of TUNEL-positive cells. The determination of apoptotic rates could therefore be significantly biased by the pronounced differences in macrophage densities in Plg-sufficient and Plg-deprived tumors. Altogether, the causal relationship of the reduction in vessel density in Plg-deprived tumors to their impaired intradermal growth warrants further investigation.
The lack of effect of loss of uPAR on the accumulation of tumor-infiltrating macrophages is somewhat surprising, as uPAR has been reported to be required for b2 integrin-dependent leukocyte extravasation to the peritoneal cavity in response to inflammatory stimuli (May et al., 1998) . The findings in the present study therefore suggest that the requirement of uPAR for monocyte extravasation may be critically dependent of the specific physiological or pathological context in which the extravasation takes place.
Overall, the loss of stromal cell-produced Plg activator, uPAR, and PAI-1 did not have a pronounced effect on the rate of orthotopic tumor growth. However, the combined loss of stromal uPA and tPA, or of uPA alone, was associated with a tendency toward a modest growth impairment about two weeks after intradermal inoculation of the tumor cells. This finding is in agreement with a recent study reporting that stromal uPA was important for T241 fibrosarcoma growth beyond the second week of intradermal inoculation (Gutierrez et al., 2000) , but does not lend support to the notion that stromal PAI-1 is of general importance in tumor angiogenesis (Bajou et al., 1998) . It is possible that the total amount of PAI-1 in a tumor is the more critical factor in tumor angiogenesis, rather than the specific site of production (stromal cells or tumor cells). If this is the case, the precise amount of tumor cell-produced PAI-1 would determine the overall importance of stromal PAI-1 in tumor progression (Devy et al., 2002; McMahon et al., 2001) , which could explain the discrepancies between the findings in this paper and a previous report (Gutierrez et al., 2000) . Importantly, however, the loss of both stromal and tumor cell-produced PAI-1 was recently found to have no effect on tumorigenesis, invasion, or metastasis in a genetic model of metastatic mammary adenocarcinoma, showing that PAI-1 is not a universal proangiogenic factor in tumor biology (Kasper Amholt, Keld Danø, and Morten Johnsen, personal communication) .
One issue that needs particular attention when performing studies that include the prolonged growth of Plg activator and PAI-1-expressing tumors in immunocompetent mice that are genetically deficient in these factors, is the possibility of eliciting a specific immune response directed against these proteins. Plg activators and PAI-1 are foreign antigens in Plg activator and PAI-1 deficient mice, and uPA, tPA and PAI-1-deficient mice have all been shown to mount a vigorous immune response within 2 weeks of being immunized with murine uPA, tPA, and PAI-1, respectively (Declerck et al., 1995a,b) . Thus, it is throughout possible that the trend towards a slight growth disadvantage that was observed in Plg activator-deficient mice after prolonged intradermal tumor growth could be the consequence of the elicitation of a specific immune response directed against cell surface-localized uPA. In agreement with this notion, we did observe a significant increase in the number of peritumoral CD3-positive lymphocytes in uPA7/7 mice after 2 weeks of intradermal tumor growth (data not shown).
In summary, we have shown that Plg and tumorproduced Plg activator contributes to orthotopic T241 fibrosarcoma growth, and to suppression of the accumulation of tumor-infiltrating macrophages and angiogenesis, independently of stromal PA, uPAR, and PAI-1.
Materials and methods

Gene targeted mice
The generation of gene targeted mice has been described previously (Bugge et al., 1995a (Bugge et al., ,b, 1996a Carmeliet et al., 1993 Carmeliet et al., , 1994 . All mice were backcrossed at least seven times to C57BL6/J prior to tumor cell inoculation. The mice were housed in a pathogen-free AAALAC certified facility and the study was carried out in accordance with Institutional guidelines. Mice with single and combined deficiencies in the PA system were generated by interbreeding of mice with the appropriate genotypes. The genotype of the animals was determined by PCR using DNA derived from ear biopsies at weaning. The genotypes of targeted and endogenous Plg, uPA, tPA, and uPAR alleles were determined as described previously (Bugge et al., 1996a,b) . The presence of the targeted and wild type PAI-1 alleles was determined by multiplex PCR using the following primers: mPAI1.1p: 5'-TTCATGCCCTCTGGTCGCTG-3', hybridizing to position 747 to 766 in the murine PAI-1 gene (Prendergast et al., 1990) , mPAI1.2m: 5'-CTCCCTCCCTCCCAGTGACTTG-3', hybridizing to position 1095 to 1074 in the murine PAI-1 gene, and mPGK2m: 5'-GCCTTGGGAAAAGCGCCTC-3', hybridizing to position 1092 to 1074 of the murine phosphoglycerate kinase-1 gene promoter (Boer et al., 1990) .
Cell culture and tumor transplantation T241 fibrosarcoma (Liotta et al., 1980) was kindly provided by Dr Todd Hembrough, Entremed, Rockville, MD, USA.
The cells were expanded in culture in a 10% CO 2 -buffered incubator in DMEM supplemented with 1 mM sodium pyruvate, non-essential amino acid mix, MEM Eagle essential amino acid mix, MEM essential vitamin mix, L-glutamine, penicillin/streptomycin/fungizone mix (all from BioWhittaker, Walkersville, MD, USA), and 10% fetal bovine serum (Hyclone, Logan, UT, USA). Prior to injection, the tumor cells were detached by trypsinization, washed once in medium with 10% serum and once in ice-cold serum-free medium. Cell viability was determined by Trypan blueexclusion and was typically 490%. The dorsal skin of mice was shaved one day prior to injection. The mice were anesthetized by Isoflurane inhalation, and tumor cells (0.3610 6 Trypan blue-excluding cells in 100 ml serum-free medium) were injected into the dorsal subcutis using a 27 gauge needle. The weight of intradermal tumor nodules was estimated by the standard method of calipation used routinely to measure the growth of intradermal tumors (Geran et al., 1972) . The short and long diameters of the tumors were measured with calipers, and the tumor weight was calculated by assuming a hemiellipsoid shape and using the following formula: grams=[(width) 2 6length]/2. To comply with institutional guidelines, the experiments were terminated 14 -19 days after tumor cell inoculation when one or more mice in the cohort displayed signs of overt distress due to tumor morbidity. All mice were regenotyped at the termination of the experiment to verify the genotype.
Laser capture microdissection
Mice were inoculated with tumor cells as described above. Seven days after inoculation, the tumor-bearing mice were anesthetized by a brief inhalation of CO 2 and perfused intracardially with 10 ml ice-cold phosphate buffered saline. The tumors were excised, bisected along the longest axis, embedded in OCT, and immediately frozen in liquid N 2 . Six to 7 um cryostat sections of the frozen tumor were generated and briefly stained (20 s) with hematoxylin and eosin. Fifty mM EDTA, 0.5 mg/ml Leupeptin (BachemCalifornie Inc., Torrance, CA, USA), and 0.7 mg/ml pepstatin (Roche Diagnostics, Indianapolis, IN, USA) were added to all waterbased staining solutions to prevent proteolytic degradation. The sections were dehydrated in graded ethanol solutions and xylene, and subjected to laser capture microdissection using an Arcturus PixCell II microscope (Arcturus Engineering, Mountain View, CA, USA) as described previously (Leethanakul et al., 2000) .
Casein plasminogen zymography
Tumor samples obtained by laser capture microdissection were lysed in non-reducing SDS -PAGE sample buffer. Seven mg protein samples were resolved by SDS -PAGE under nonreducing conditions on a 12% gel that incorporated 1% boiled, nonfat dry milk, with or without 20 mg/ml Plg (Sawaya and Highsmith, 1988) . The gel was washed twice for 30 min each in 2.5% Triton X-100 to remove SDS and renature proteins, and developed overnight in 0.1 M glycine, pH 8.0, at 378C. The gel was stained with 0.1% Amido Black (BioRad Laboratories, Hercules, CA, USA), and destained in 30% methanol and 10% acetic acid solution to visualize the zones of lysis.
Western blot analysis
Tumor samples obtained by laser capture microdissection were lysed in non-reducing SDS -PAGE sample buffer. Total protein lysates (10 mg) were separated on a 4 -20% TrisGlycine gel (Invitrogen, Carlsbad, CA, USA), transferred to Protran nitrocellulose transfer membrane (Schleicher and Schuell, Dassel, Germany), blocked overnight with 1% bovine serum albumine (BSA) in Tris buffered saline (TBS) at 48C, and then rinsed three times between each step with 0.1% BSA, 0.05% Tween-20 in TBS. The membrane was incubated with a primary rabbit anti-murine PAI-1 antibody (Molecular Innovation, Boston, MA, USA) at 1 : 1000 dilution in 0.1% BSA, 0.05% Tween-20 in TBS at room temperature for 1 h, followed by incubation for 30 min with a biotinylated donkey anti-rabbit secondary antibody (Jackson Immuno Research, Westgrove, PA, USA) at 1 : 20 000 dilution in 1% BSA in TBS, and developed with the Ultra-Sensitive ABC Staining Reagent (Pierce, Rockford, IL, USA).
Northern blot analysis
Mice were anesthetized by a brief inhalation of CO 2 and perfused intracardially with 10 ml ice-cold phosphate buffered saline. Tumors and liver were excised, snap-frozen in liquid nitrogen, and ground to a fine powder with a mortar and pestle. Total RNA was prepared by extraction in Trizol reagent (Gibco -BRL), as recommended by the manufacturers. Samples (10 mg) were fractionated electrophoretically on formaldehyde agarose gels, blotted onto NytranSuperCharge nylon membranes (Schleicher and Schuell, Keene, NH, USA), hybridized to 32 P-labeled murine Plg and GAPDH cDNA probes, and subjected to PhosphorImage analysis using ImageQuant software from Molecular Dynamics (Molecular Dynamics, Sunnyvale, CA, USA).
Histological analysis
Tumor-bearing mice were anesthetized by a brief inhalation of CO 2 and perfused intracardially with 10 ml ice-cold phosphate buffered saline followed by 10 ml of 4% paraformaldehyde (Electron Microscopy Sciences, Fort Washington, PA, USA). The tumors were excised, bisected along the longest axis, fixed for 24 h in 20 volumes 4% paraformaldehyde in phosphate buffered saline, processed into paraffin, sectioned and stained with hematoxylin/eosin, Masson's trichrome, or immunostained, as described below.
Immunostaining was performed with a Vectastain ABC peroxidase kit (Vector Laboratories, Inc., Burlingame, CA, USA) using diaminobenzidine as chromogenic substrate. Endothelial cells were stained with rat anti-mouse CD31 (PECAM-1) (Pharmingen, San Diego, CA, USA) and biotinylated rabbit anti-rat IgG (Vector Laboratories). Fibrin(ogen) was detected with rabbit anti-mouse polyclonal antiserum as described previously (Bugge et al., 1997) . B lymphocytes were detected with biotinylated rat anti-mouse CD45R/B220 (Pharmingen). T lymphocytes were detected with rabbit anti-human T cell antibodies (DAKO, Carpinteria, CA, USA). Macrophages were detected with rat antimouse F4/80 (Caltag Laboratories, Burlingame, CA, USA) and biotinylated rabbit anti-rat IgG (Vector Laboratories). Apoptotic nuclei were visualized by TUNEL staining using an Apotag kit (Intergen, Gaithersburg, MD, USA) as recommended by the manufacturers. Tumor-bearing mice were injected with BrdU 2 h prior to sacrifice and cell proliferation was visualized by staining with BrdU antibodies. Quantitation of proliferating cells, apoptotic nuclei, vessels, macrophages, B, and T lymphocyte densities, was performed by an investigator unaware of animal genotype, using an ocular grid and a 406 objective (approximately 300 cells/ocular grid), typically counting 6 -10 random sections per tumor. The extent of fibrin(ogen) deposition in necrotic areas, the invasive front, tumor vessels, and healthy tumor tissue was assessed on day 15 by an investigator unaware of animal genotype and arbitrarily graded by a scale from 1 to 3, analysing nine tumors from Plg7/7 mice and 11 tumors from control mice.
